Literature DB >> 18222385

Management of peristomal pyoderma gangrenosum.

Lisa S Poritz1, Marjorie A Lebo, Anne D Bobb, Christine M Ardell, Walter A Koltun.   

Abstract

BACKGROUND: Pyoderma gangrenosum (PG) occurs in about 1% to 5% of patients with inflammatory bowel disease (IBD). Peristomal pyoderma gangrenosum (PPG) is particularly difficult to manage. STUDY
DESIGN: A retrospective chart review was performed on all patients with IBD in whom PPG developed from 1997 to 2007 at the Milton S Hershey Medical Center.
RESULTS: Sixteen patients (11 women) were identified. Seven had Crohn's disease (CD), seven had ulcerative colitis (UC), and two had indeterminate colitis. Six patients underwent total proctocolectomy, six patients had total abdominal colectomy (TAC), and four patients had diverting loop stomas. PPG occurred an average of 18.4+/-7.5 months after stoma creation. Twelve patients had active IBD when PPG developed. Two patients had stoma revisions and both had recurrence of the PPG with the new stoma. Medical therapy was successful in eight patients. Five patients had their stomas closed, with active PPG, and all five resolved their lesions. In four of five, surgical management was altered because of PPG (one early stoma closure, two ileal pouches without stomas, one ileal pouch with high body mass index). Of the seven and six patients treated with cyclosporine or infliximab, respectively, there were only two successes with each.
CONCLUSIONS: PPG is more common in the presence of active IBD. Surgical closure of the stoma was successful in resolving PPG in all patients. Cure rate of PPG was poor with cyclosporine and only marginally better with infliximab. Medical treatment of PPG is imperfect, and the best therapy is stoma closure when possible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18222385     DOI: 10.1016/j.jamcollsurg.2007.07.023

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  8 in total

1.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

Review 2.  A novel topical therapy for resistant and early peristomal pyoderma gangrenosum.

Authors:  Wendy A Pearson; David A Prentice; Deborah L Sinclair; Lee Y Lim; Keryln J Carville
Journal:  Int Wound J       Date:  2019-07-12       Impact factor: 3.315

3.  Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.

Authors:  F Argüelles-Arias; L Castro-Laria; T Lobatón; M Aguas-Peris; M Rojas-Feria; M Barreiro-de Acosta; P Soto-Escribano; M Calvo-Moya; D Ginard-Vicens; M Chaparro-Sánchez; M Hernández-Durán; B Castro-Senosiain; A Fernández-Villaverde; V García-Sánchez; E Domínguez-Muñoz; A Caunedo-Álvarez; J M Herrerías-Gutiérrez
Journal:  Dig Dis Sci       Date:  2013-07-05       Impact factor: 3.199

Review 4.  Ostomy Complications in Crohn's Disease.

Authors:  Armen Aboulian
Journal:  Clin Colon Rectal Surg       Date:  2019-06-17

5.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 6.  Avoidance and management of stomal complications.

Authors:  Michael Kwiatt; Michitaka Kawata
Journal:  Clin Colon Rectal Surg       Date:  2013-06

7.  Pyoderma gangrenosum occurring at the peri-ileal pouch-anal anastomosis in a patient with ulcerative colitis: report of a case.

Authors:  Koji Tanaka; Toshimitsu Araki; Yoshiki Okita; Hiroyuki Fujikawa; Mikio Kawamura; Keiichi Uchida; Yasuhiko Mohri; Masato Kusunoki
Journal:  Surg Today       Date:  2012-12-22       Impact factor: 2.549

8.  Severe pyoderma gangrenosum in association with a flame burn.

Authors:  Kaho Matsuda; Osamu Okamoto; Seiichi Sato; Ayako Gamachi; Hiroyuki Hashimoto
Journal:  Case Reports Plast Surg Hand Surg       Date:  2016-03-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.